8-K - Wave Life Sciences Ltd. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Wave Life Sciences announced positive interim Phase 1 data from the INLIGHT trial of WVE-007, showing placebo-adjusted reductions in visceral fat (-14%; p<0.01) and waist circumference (-5.8 cm) at six months after a single 240 mg dose, with muscle preservation. The company plans to initiate the Phase 2a multidose portion in individuals with BMI 35-50 kg/m² in Q2 2026.

Key Takeaways

1Single 240 mg dose of WVE-007 achieved -14% placebo-adjusted visceral fat reduction (p<0.01) at 6 months

2Placebo-adjusted waist circumference reduction of -5.8 cm at 6 months

3Preserved lean muscle mass with >500g loss only in placebo arm

4Phase 2a multidose study (BMI 35-50 kg/m², comorbidities) to initiate Q2 2026

5Additional Phase 1 data from 600 mg SAD cohort expected in 2026

6Investor conference call held March 26, 2026 at 8:30 a.m. ET

Current Report Details

Event Type

Regulation Fd

Other Event

Disclosure

Voluntary

Variant

8-K

Items Reported

7.01

is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherw

Regulation Fd

8.01

of this Current Report on Form 8-K. Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release issued by Wave Life Sci

Other Event

Exhibits (2)

8-K

99.1

EX-99.1